31 Mar 2021
Assets1,182.55
Total Income630.75
Profit After Tax234.89
NET Worth999.37
Total Borrowing86.35
At a glance
Updated 2026-09-16The shares listed at ₹900.05, a 21.46% move from the issue price. Concord Biotech is a Mainboard IPO with an issue size of ₹1,550.52 crore, proposed for listing on BSE, NSE. The offer opens on 4th Aug 2023 and closes on 8th Aug 2023. The issue structure includes an offer-for-sale component of ₹1,550.52 crore. The current listing schedule points to 18th Aug 2023.
Issue details
Listing atBSE, NSE
Issue typeBook Build Issue
Issue size₹1,550.52 Cr
Offer for sale₹1,550.52 Cr
Face value₹1
Price band₹705.00–₹741.00
Allotment11th Aug 2023
Listing18th Aug 2023
Listing performance
Full performance ↗Issue price₹741.00
Listing price₹900.05
Current price—
Listing gain21.46%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹122.00
GMP / upper price16.46%
Est. listing₹863.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens4th Aug 2023
Closes8th Aug 2023
Allotment11th Aug 2023
Refund14th Aug 2023
Demat17th Aug 2023
Listing18th Aug 2023
Subscription demand
Full bidding ↗Total24.87×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 20 | ₹14,820 |
Company
Incorporated1984
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue888.48₹ Cr · +20.7% vs prior year
PAT240.08₹ Cr · +37.2% vs prior year
Assets1,513.98₹ Cr · +15.3% vs prior year
Net Worth1,290.00₹ Cr · +16.9% vs prior year
Borrowing31.24₹ Cr · -48.4% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2022
Assets1,312.80
Total Income736.35
Profit After Tax174.93
NET Worth1,103.22
Total Borrowing60.59
31 Mar 2023
Assets1,513.98
Total Income888.48
Profit After Tax240.08
NET Worth1,290.00
Total Borrowing31.24
KPIs
| KPI |
|---|
| ROE |
| ROCE |
| RoNW |
| PAT Margin |
Valuation & shareholding
Pre-IPO EPS20.79
Pre-IPO P/E32.29
Promoter holding pre44.08%
Promoter holding post44.08%
Market cap₹7752.06 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Concord Biotech IPO | — | - | — | — |
| Symbiotec Pharmalab IPO | — | 61.88 x | — | — |
| Sai Parenteral's IPO | — | 111.58 x | — | — |
| Corona Remedies IPO | — | 35.15 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Book Running Lead Managers' fees including underwriting commission | ₹33.02 Cr |
| Commission/processing fee for SCSB, Sponsor Banks and Bankers to the Offer. Brokerage, underwriting commission and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs(2)(3)(4)(5) | ₹5.43 Cr |
| Fees payable to the Registrar to the Offer | ₹0.28 Cr |
| Others | — |
| Auditor, independent chartered accountant, industry expert, intellectual property consultant, etc. | ₹5.68 Cr |
| Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | ₹4.84 Cr |
| Printing and stationery | ₹1.49 Cr |
| Advertising and marketing expenses | ₹5.48 Cr |
| Fees payable to legal counsels | ₹9.04 Cr |
| Miscellaneous | ₹2.33 Cr |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- Kotak Mahindra Capital Co.Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-16.
IPO UPDATE ALERTS
Register for IPO Updates →Track Concord Biotech without missing an update
Register for subscription, GMP, allotment and listing notifications.